Tretinoin can make minoxidil more effective for hair loss treatment, but some users did not see improved hair density with this combination and had better results with dutasteride.
User asks about CB-03-01 for hair loss treatment and mentions using topical Dutasteride, TRT, and considering mixing CB-03-01 with Fluridil. CB-03-01 is sold at a high price, and user considers trying a lower concentration.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
User experienced good results with topical finasteride, noting reduced DHT and increased testosterone. They plan to revert to a lower dosage after observing slight libido reduction.
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.
A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.
A user's 11-month hair loss treatment progress using 0.5mg dutasteride every other day, 50mg RU58841 in the morning, 5mg oral minoxidil, topical minoxidil at night, and microneedling with a 1.5mm needle every other week. The user's improvement was significant, going from a severe hair loss stage (NW7) to a mild/moderate stage (NW2-3).
The conversation is about the anticipated release timeline for a hair loss treatment called GT20029. It may be available on the gray market in 1-2 years and officially in 3-4 years after completing clinical trials.
A 27-year-old man shared his hormonal panel results after one year of taking finasteride 1mg/day for hair loss, showing his DHT levels nearly doubled. He reported stabilized hair loss with mild side effects that resolved, and he is considering a hair transplant but is concerned about the increased DHT levels and potential treatment options.
The user, on testosterone replacement therapy, found finasteride and minoxidil ineffective for hair loss. They are trying a new topical gel with dutasteride, tretinoin, and a higher concentration of minoxidil, and plan to document the results.
A 43-year-old male with advanced hair loss is experimenting with alternative treatments, including red light therapy, microneedling, scalp massages, an oil mix, and ketoconazole shampoo, after previously experiencing side effects from finasteride and minoxidil. He noticed some minor changes with red light therapy but remains skeptical about significant improvement.
Switching from finasteride to dutasteride and back to finasteride led to gynecomastia and fatigue, likely due to hormonal imbalances. Suggested treatments include Tamoxifen, Raloxifene, or low-dose Anastrozole, with a recommendation to test testosterone and estradiol levels.
A user ordered RU58841 from a Chinese supplier, found it to be less than 99% pure, and plans to try a different seller next time. Concerns were raised about impurities, but the user believes they are likely inactive fillers rather than harmful substances.
The conversation discusses hair regrowth possibilities using finasteride, minoxidil, microneedling, and dutasteride, with the user experiencing improvement from NW4 to NW2. Achieving NW0 is deemed unrealistic, but further regrowth may be possible with patience and potentially a hair transplant.
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.
A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.
A 25-year-old male experienced increased testosterone and estradiol levels after starting finasteride for hair loss, leading his doctor to suggest a testicular ultrasound as a precaution. The user questions the necessity of the ultrasound, considering it potentially excessive, while others suggest it could be a useful precaution to rule out any issues.
A user shared their positive experience with Trichogenics for hair restoration, highlighting their unique zigzag hairline technique and personalized attention. They had 1700 follicles transplanted and praised the natural results.
A user saw no results from using minoxidil and microneedling for 1.5 years and is considering trying tretinoin. They are seeking others' experiences with tretinoin for hair loss.
Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.
A user shared a 10-month update on their hair transplant (HT), expressing significant confidence gain and recommending the procedure to others. They had the transplant in Turkey for $2300 and are very satisfied with the results.
A user is considering an extensive hair loss treatment regimen including oral dutasteride, oral minoxidil, topical finasteride, tretinoin, microneedling, keto shampoo, laser comb, and PRP injections. Suggestions include simplifying the routine, possibly increasing minoxidil dosage, and considering alternatives like RU58841, while cautioning against using estrogen due to potential side effects.
People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.
Tazarotene's potential to enhance Minoxidil conversion, similar to Tretinoin, is questioned. Users discuss the lack of information and seek further details.
Hair transplant recipients are concerned about whether dormant follicles are permanently damaged by incisions, but some believe undamaged follicles could still regrow if a treatment like PP405 is effective. Opinions vary on the impact of transplants on original follicles, with some suggesting treatments like finasteride can help regrow hair.
The user is using RU58841, finasteride, dutasteride, and minoxidil to slow down aggressive hair loss but is still experiencing hair shedding due to high testosterone levels. They plan to use ostarine to lower testosterone and prevent hair loss while maintaining muscle mass, and will continue using the other treatments.
Hair loss treatments discussed include alfatradiol, big 3, finasteride, RU58841, and stemoxydine. Alfatradiol is less effective but has fewer side effects, and mixing with stemoxydine may improve results.